About: CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation
Creator	Andersen-Elyard, Hanne Biology, Molecular Burns School, John Haun, Brien Lai, Chih-Yun Lehrer, Axel Lieberman, Pessaint, Laurent Program, Graduate Williams, Caitlin Wong, Teri
Source	BioRxiv; Medline
abstract	The current COVID-19 pandemic has claimed hundreds of thousands of lives and its causative agent, SARS-CoV-2, has infected millions, globally. The highly contagious nature of this respiratory virus has spurred massive global efforts to develop vaccines at record speeds. In addition to enhanced immunogen delivery, adjuvants may greatly impact protective efficacy of a SARS-CoV-2 vaccine. To investigate adjuvant suitability, we formulated protein subunit vaccines consisting of the recombinant S1 domain of SARS-CoV-2 Spike protein alone or in combination with either CoVaccine HT™ or Alhydrogel. CoVaccine HT™ induced high titres of antigen-binding IgG after a single dose, facilitated affinity maturation and class switching to a greater extent than Alhydrogel and elicited potent cell-mediated immunity as well as virus neutralising antibody titres. Data presented here suggests that adjuvantation with CoVaccine HT™ can rapidly induce a comprehensive and protective immune response to SARS-CoV-2.
has issue date	2020-07-26(xsd:dateTime)
bibo:doi	10.1101/2020.07.24.220715
bibo:pmid	32743582
has license	biorxiv
sha1sum (hex)	3f69b0e77b70b5b603b42d56493f051764ddabec
schema:url	https://doi.org/10.1101/2020.07.24.220715
resource representing a document's title	CoVaccine HT™ adjuvant potentiates robust immune responses to recombinant SARS-CoV-2 Spike S1 immunisation
has PubMed identifier	32743582
schema:publication	bioRxiv
resource representing a document's body	covid:3f69b0e77b70b5b603b42d56493f051764ddabec#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'potent' named entity 'vaccines' named entity 'IgG' named entity 'pandemic' named entity 'COVID-19' named entity 'protein subunit' named entity 'globally' named entity 'adjuvant' named entity 'dose' named entity 'adjuvants' named entity 'Alhydrogel' named entity 'cell-mediated immunity' named entity 'COVID-19 pandemic' named entity 'immunisation' named entity 'immune responses' named entity 'adjuvant' named entity 'protein' named entity 'receptor binding' named entity 'SARS-2' named entity 'emulsion' named entity 'SARS' named entity 'SARS-CoV-2' named entity 'adjuvants' named entity 'adjuvanted' named entity 'SARS' named entity 'single cell' named entity 'Serum analysis' named entity 'immunisations' named entity 'IFN' named entity 'SARS-CoV-2' named entity 'immunogen' named entity 'SARS-CoV-2' named entity 'adjuvant' named entity 'immunised' named entity 'IgG antibodies' named entity 'antigen' named entity 'IgG' named entity 'cellular immune response' named entity 'microsphere' named entity 'cross reactivity' named entity 'protein subunit' named entity 'sera' named entity 'MF59' named entity 'vaccine' named entity 'adjuvants' named entity 'immunisation' named entity 'IgG1' named entity 'adjuvant' named entity 'phosphate buffered saline' named entity 'Alum' named entity 'Alum' named entity 'cross-reactivity' named entity 'spleens' named entity 'peptide' named entity 'fluorescence' named entity 'peptide' named entity 'squalane' named entity 'SARS' named entity 'Alum' named entity 'adjuvants' named entity 'Alhydrogel' named entity 'biosafety level 3' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'Alum' named entity 'Alhydrogel' named entity 'adjuvants' named entity 'neutralising antibody' named entity 'humoral response' named entity 'IFN' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software